What are alternative treatments to Linzess (linaclotide) for chronic constipation or irritable bowel syndrome with constipation (IBS‑C)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 10, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Alternatives to Linzess for Chronic Constipation and IBS-C

For patients seeking alternatives to Linzess (linaclotide), start with polyethylene glycol (PEG) 17g daily as first-line therapy due to its proven efficacy, excellent safety profile, and low cost ($10-45/month), then escalate to prescription alternatives like plecanatide (3mg daily, $526/month) or prucalopride (1-2mg daily, $563/month) if symptoms persist. 1

Algorithmic Approach to Linzess Alternatives

Step 1: Over-the-Counter Options (First-Line)

Osmotic Laxatives - These should be your initial choice:

  • Polyethylene Glycol (PEG): 17g daily, titrate based on response. This has durable efficacy demonstrated over 6 months. Common side effects include bloating, abdominal discomfort, and cramping, but these are generally mild. Cost: $10-45/month 1

  • Magnesium oxide: 400-500mg daily (studies used 1,000-1,500mg daily). Critical caveat: Use with extreme caution in renal insufficiency and pregnancy. Cost: <$50/month 1

  • Lactulose: 15g daily. This is the only osmotic agent studied in pregnancy, making it the preferred choice for pregnant patients. Bloating and flatulence may limit tolerability at higher doses. Cost: <$50/month 1

Step 2: Prescription Alternatives (When OTC Fails)

Same Class as Linzess (Intestinal Secretagogues):

  • Plecanatide: 3mg once daily. This is the most direct alternative to Linzess, working through the same guanylate cyclase-C mechanism. It's also FDA-approved for both IBS-C and CIC. Diarrhea occurs in a subset of patients leading to discontinuation. Cost: $526/month 1, 2

  • Lubiprostone: For IBS-C use 8mcg twice daily; for CIC use 24mcg twice daily. This chloride channel-2 activator may benefit abdominal pain. Important distinction: Lubiprostone has unique side effects including dyspnea (13% of reports) and chest pain (9.3% of reports) not seen with other agents 3. Cost: $374/month 1, 2

Different Mechanism - Prokinetic Agent:

  • Prucalopride: 1-2mg daily (max 2mg daily). This 5-HT4 agonist may provide additional benefit for abdominal pain beyond constipation relief. Headaches and diarrhea may occur. This represents a mechanistically distinct option when secretagogues fail. Cost: $563/month 1

Step 3: Short-Term/Rescue Therapy

Stimulant Laxatives - Reserve for breakthrough symptoms:

  • Bisacodyl: 5mg daily (max 10mg daily). Recommended for short-term use or rescue therapy only. Prolonged use can cause diarrhea and electrolyte imbalance. Long-term safety unknown. Cost: <$50/month 1

  • Senna: 8.6-17.2mg daily (max 4 tablets twice daily). Also present in many laxative teas where dosing is difficult to calculate. Long-term safety unknown. Cost: <$50/month 1

Key Clinical Considerations

Efficacy Comparison: Network meta-analysis demonstrates that all secretagogues (linaclotide, plecanatide, lubiprostone, tenapanor) are superior to placebo for IBS-C, with similar efficacy among individual drugs for most endpoints at the 12-week timepoint 4. Linaclotide 290mcg ranked first for FDA composite endpoints and abdominal pain relief, but plecanatide and lubiprostone are reasonable alternatives with comparable efficacy 4.

Safety Profile Differences:

  • Diarrhea is the most common adverse event across all secretagogues: linaclotide (24.1% of reports), plecanatide (20.4%), but only 4.7% with lubiprostone 3
  • Lubiprostone uniquely causes dyspnea (13%) and chest pain (9.3%) - critical to counsel patients about these symptoms 3
  • Clinically significant dehydration can occur with linaclotide-induced diarrhea 3

Cost-Effectiveness Strategy: The evidence strongly supports starting with PEG given its proven 6-month durability, minimal side effects, and dramatically lower cost ($10-45 vs $523-563/month for prescription agents) 1. Only escalate to prescription agents when OTC options fail after adequate trial (minimum 4-6 weeks).

Special Populations:

  • Pregnancy: Lactulose is the only osmotic agent studied in pregnancy 1
  • Renal insufficiency: Avoid magnesium oxide 1
  • Pediatric patients 6-17 years: Linaclotide 72mcg is FDA-approved for functional constipation 5
  • Patients <2 years: Linaclotide is contraindicated due to risk of fatal dehydration 5

Common Pitfalls to Avoid

  1. Don't skip OTC options: Many clinicians jump directly to expensive prescription agents. PEG has robust evidence and should be tried first unless contraindicated 1

  2. Don't ignore the abdominal pain component: If abdominal pain is the predominant symptom in IBS-C, lubiprostone or prucalopride may offer additional benefit beyond constipation relief 1, 2

  3. Don't use stimulant laxatives long-term: Bisacodyl and senna lack long-term safety data and should be reserved for rescue therapy 1

  4. Don't forget to counsel about diarrhea: All secretagogues carry significant diarrhea risk. Patients should be instructed to suspend dosing and rehydrate if severe diarrhea occurs 5, 3

  5. Don't overlook lubiprostone's unique side effects: The dyspnea and chest pain associated with lubiprostone can be alarming to patients and may be mistaken for cardiac symptoms 3

References

Related Questions

In a patient with chronic constipation who has failed linaclotide (Linzess) 290 µg and plecanatide (Trulance) and remains constipated, what is the next recommended treatment?
What is the first-line treatment for a patient with irritable bowel syndrome with constipation (IBS-C)?
What constipation treatments are alternatives to linaclotide (Linzess) that are covered by Blue Cross Blue Shield PPO?
What is the appropriate management for diarrhea caused by IBS therapy (e.g., linaclotide, plecanatide, lubiprostone, alosetron)?
In chronic idiopathic constipation or IBS‑C, how do Amitiza (lubiprostone) and Linzess (linaclotide) compare regarding dosing, contraindications, side‑effect profile, and patient suitability?
What considerations should be taken into account before starting glucagon‑like peptide‑1 (GLP‑1) receptor agonist therapy in a patient with an elevated C‑reactive protein of approximately 11 mg/L?
How should heart rate be interpreted and severity classified in an older adult (≥65 years)?
Can metronidazole (Flagyl) 500 mg four times daily and tetracycline 500 mg four times daily be used for Helicobacter pylori treatment?
What are the normal temperature ranges, fever thresholds, and management recommendations for temperature abnormalities in older adults (≥65 years)?
What is the recommended management for a 76-year-old asymptomatic woman with mild cardiomegaly?
What is the recommended treatment for chlamydia infection in patients allergic to penicillin and azithromycin?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.